#1 Clinical Trials Search in Europe

Pasireotide

Pasireotide is a novel somatostatin analog being investigated in clinical trials for its potential to treat several medical conditions. This article summarizes key findings from recent studies examining pasireotide’s efficacy, safety, and pharmacokinetics in diseases like Cushing’s disease, acromegaly, neuroendocrine tumors, and dumping syndrome. Researchers are evaluating both subcutaneous and long-acting release formulations of pasireotide to determine optimal dosing and assess its ability to manage hormonal imbalances and related symptoms.

Table of Contents

What is Pasireotide?

Pasireotide is a medication that belongs to a class of drugs called somatostatin analogs. It is also known by its brand name Signifor and its research code SOM230[1]. Pasireotide is designed to mimic the action of somatostatin, a natural hormone in the body that regulates various functions, including the production of other hormones[2].

How Pasireotide Works

Pasireotide works by binding to specific receptors (somatostatin receptors) in the body. It has a strong affinity for several types of these receptors, which allows it to have a broader range of effects compared to other similar medications. By attaching to these receptors, pasireotide can inhibit the production of certain hormones and reduce cell activity in various tissues[2][3].

The medication’s ability to affect multiple hormone systems makes it useful for treating several conditions related to hormone imbalances. It can help reduce the levels of hormones like cortisol, growth hormone, and insulin-like growth factor 1 (IGF-1), which are often elevated in certain diseases[4].

Conditions Treated with Pasireotide

Pasireotide is used to treat several medical conditions, including:

  • Cushing’s Disease: A condition where the body produces too much cortisol, leading to various symptoms such as weight gain, high blood pressure, and muscle weakness[4][5].
  • Acromegaly: A disorder characterized by excessive growth hormone production, resulting in enlarged hands, feet, and facial features[1].
  • Neuroendocrine Tumors: Rare tumors that can occur in various parts of the body and often produce excess hormones[1].
  • Ectopic ACTH Syndrome: A rare condition where tumors outside the pituitary gland produce excess ACTH (adrenocorticotropic hormone), leading to Cushing’s syndrome[6].

Researchers are also exploring its potential use in other conditions, such as:

  • Dumping Syndrome: A condition that can occur after certain types of stomach surgery[1].
  • Certain types of Melanoma: Specifically, melanomas that are negative for certain genetic mutations (bRAF and nRAS)[1].
  • Hyperinsulinemic Hypoglycemia: A condition where the body produces too much insulin, leading to low blood sugar levels[7].

How Pasireotide is Administered

Pasireotide is available in two main forms:

  1. Subcutaneous (SC) Injection: This form is injected under the skin, usually twice daily. The dose can range from 0.3mg to 0.9mg, depending on the condition being treated and the patient’s response[1].
  2. Long-Acting Release (LAR) Injection: This form is given as an intramuscular injection (into the muscle) once every 28 days. The dose can range from 10mg to 60mg[4].

The specific dose and form of pasireotide used will depend on the patient’s condition, their response to treatment, and any side effects experienced. It’s important to follow the dosing schedule prescribed by your healthcare provider[4].

Effectiveness of Pasireotide

Clinical trials have shown that pasireotide can be effective in treating various hormone-related conditions:

  • In Cushing’s Disease, pasireotide has been shown to reduce cortisol levels in many patients, leading to improvements in symptoms[4].
  • For patients with Acromegaly, pasireotide can help control growth hormone and IGF-1 levels[1].
  • In cases of Ectopic ACTH Syndrome, pasireotide has shown promise in normalizing cortisol levels[6].

However, it’s important to note that the effectiveness can vary from person to person, and not all patients will respond to the treatment in the same way[4].

Side Effects and Safety Considerations

Like all medications, pasireotide can cause side effects. Some of the most common side effects include:

  • Gastrointestinal issues: Such as nausea, diarrhea, and abdominal pain[8].
  • Changes in blood sugar levels: Pasireotide can cause an increase in blood sugar levels, especially in the early stages of treatment. This effect may improve over time, but it’s important for patients to monitor their blood sugar regularly[8].
  • Gallbladder issues: Some patients may develop gallstones[5].
  • Injection site reactions: Such as pain or irritation at the injection site[4].

Your healthcare provider will monitor you closely for these and other potential side effects. It’s important to report any unusual symptoms or changes in your health to your doctor[5].

Ongoing Research and Future Potential

Researchers continue to study pasireotide to better understand its effects and explore its potential in treating other conditions. Some areas of ongoing research include:

  • Breast Cancer Prevention: Studies are investigating whether pasireotide could help prevent breast cancer in high-risk individuals by inhibiting certain growth factors[8].
  • Sarcomas: Research is being conducted on the use of pasireotide in certain types of sarcomas, such as synovial sarcoma and desmoplastic small round cell tumors[9].
  • Long-term effects: Studies are ongoing to assess the long-term safety and efficacy of pasireotide in various conditions[5].

As research continues, our understanding of pasireotide and its potential uses may expand, potentially offering new treatment options for patients with various hormone-related conditions[9].

Aspect Details
Drug Name Pasireotide (also known as SOM230, Signifor)
Drug Class Somatostatin analog
Mechanism of Action Binds to multiple somatostatin receptors to inhibit hormone secretion
Formulations Subcutaneous injection, Long-acting release (LAR) intramuscular injection
Conditions Studied Cushing’s disease, Acromegaly, Neuroendocrine tumors, Dumping syndrome, Synovial sarcoma, Desmoplastic small round cell tumors
Key Outcomes Measured Hormone levels (e.g., cortisol, growth hormone), Tumor size, Symptom improvement, Quality of life
Common Side Effects Hyperglycemia, Gastrointestinal issues, Gallbladder-related problems
Current Status Approved for some indications, Investigational for others

FAQ

  • What is pasireotide and how does it work? Pasireotide is a somatostatin analog that binds to multiple somatostatin receptors. It works by inhibiting the secretion of hormones like ACTH, growth hormone, and insulin. This allows it to potentially treat conditions involving hormonal overproduction or imbalance.
  • What medical conditions is pasireotide being studied for? Clinical trials are investigating pasireotide for conditions including Cushing's disease, acromegaly, neuroendocrine tumors, dumping syndrome, and certain types of cancer like synovial sarcoma and desmoplastic small round cell tumors.
  • How is pasireotide administered? Pasireotide is given as either subcutaneous injections (typically twice daily) or as a long-acting release (LAR) intramuscular injection given monthly. The specific dosing depends on the condition being treated and individual patient factors.
  • What are some potential side effects of pasireotide? Common side effects observed in trials include hyperglycemia (high blood sugar), gastrointestinal effects like nausea and diarrhea, and gallbladder-related issues. Blood sugar levels are closely monitored in patients receiving pasireotide.
  • Is pasireotide currently approved for use? Pasireotide is approved in some countries for treating Cushing's disease and acromegaly in certain patient populations. However, it remains investigational for many of the conditions being studied in ongoing clinical trials.

Ongoing Clinical Trials on Pasireotide

  • Study on Pasireotide for Patients with Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Somatostatin: A hormone that inhibits the release of several other hormones and has a wide range of effects in the body.
  • ACTH: Adrenocorticotropic hormone, produced by the pituitary gland to stimulate cortisol production.
  • Cushing's disease: A condition caused by excessive cortisol production, often due to a pituitary tumor.
  • Acromegaly: A hormonal disorder caused by excess growth hormone production, typically from a pituitary tumor.
  • Neuroendocrine tumors: Rare tumors that develop from cells of the endocrine and nervous systems.
  • Dumping syndrome: A condition that can occur after stomach surgery, causing rapid emptying of stomach contents into the small intestine.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Subcutaneous: Administered beneath the skin.
  • Intramuscular: Administered into a muscle.
  • Long-acting release (LAR): A formulation designed to release the drug slowly over an extended period.
  • Hyperglycemia: Elevated blood sugar levels.
  • Urinary free cortisol (UFC): A measure of cortisol levels in urine, used to diagnose and monitor Cushing's syndrome.
  • Desmoplastic small round cell tumor: A rare and aggressive type of soft tissue sarcoma.
  • Synovial sarcoma: A rare type of cancer that typically occurs near large joints.

References

  1. https://clinicaltrials.gov/study/NCT01794793
  2. https://clinicaltrials.gov/study/NCT01356862
  3. https://clinicaltrials.gov/study/NCT01252251
  4. https://clinicaltrials.gov/study/NCT01374906
  5. https://clinicaltrials.gov/study/NCT02310269
  6. https://clinicaltrials.gov/study/NCT02780882
  7. https://clinicaltrials.gov/study/NCT03103009
  8. https://clinicaltrials.gov/study/NCT01372618
  9. https://clinicaltrials.eu/trial/study-on-pasireotide-for-patients-with-synovial-sarcoma-and-desmoplastic-small-round-cell-tumor/